Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

Peer Review reports

Original Submission
16 Feb 2012	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
8 Jun 2012	Reviewed	Reviewer Report - Nikoletta Lendvai
16 Jun 2012	Reviewed	Reviewer Report - Craig Hofmeister
6 Jul 2012	Author responded	Author comments - Roman Hajek
Resubmission - Version 3
6 Jul 2012	Submitted	Manuscript version 3
24 Jul 2012	Author responded	Author comments - Roman Hajek
Resubmission - Version 4
24 Jul 2012	Submitted	Manuscript version 4
Publishing
31 Jul 2012	Editorially accepted
19 Sep 2012	Article published	10.1186/1471-2407-12-415

Back to article page